Recombinant DENV1-4 VLP

• Cat.No.: VLP-05D
• Product Overview: This Dengue VLP multi-pack has been prepared in response to many customers requesting a combination pack for the purchase of all 4 Dengue VLP serotypes. We now offer a convenient multi-pack in which 1 vial of each serotype VLP is included with a 15% discount on the price compared to ordering the products individually. This multi-pack is ideal for cross-reactivity screening and other such experiments. Each pack contains:
  1 vial of 100 μg from strain Nauru/Western Pacific/1974.
  1 vial of 100 μg from strain Thailand/16681/84.
  1 vial of 100 μg from strain Sri Lanka D3/H/IMTSSA-SRI/2000/1266.
  1 vial of 100 μg from strain Dominica/814669/1981.

Specification

• Species: DENV
• Source: Human Cells
• Description: With more than one-third of the world's population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus.
  Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.

Gene Information

• Official Symbol: VLP
• Synonyms: VLP; Virus-Like Particles; VLPs